ExoCoBio, one of global top 4 for the stem cell exosome industry, announced that it received from Japanese Patent Office the patent which claims that stem cell-derived exosome is proven as an effective ingredient for alleviating dermatitis

The patent is the result of the vigorous R&D efforts made to develop therapeutic medicines with higher efficacy and safety than currently known ones in relation to dermatitis with itching and inflammation. ExoCoBio found that the technology in the patent would solve the safety problem arising from stem cell or stem cell conditioned media by using ExoSCRT exosomes isolated from adipose stem cell conditioned media and thus prove the effectiveness of exosomes for prevention, improvement, alleviation or treatment of dermatitis. Furthermore, it is anticipated that the ExoSCRT exosomes will play a scientifically pivotal role as a new medicine for dermatitis treatment.

The key points of the patent cover following:

ExoSCRT exosomes reduce the generation of inflammatory factors including inflammatory cytokine which are main causes of dermatitis;

ExoSCRT exosomes can be developed as active principles of medicine or cosmetics to prevent, alleviate or treat the dermatitis by suppressing the activity of inflammatory immune cells;

ExoSCRT exosomes promote the ceramide biosynthesis that is a key factor of skin barrier;

It was scientifically proved that ExoSCRT, technology developed by ExoCoBio for stem cell exosome production, plays a key role in producing high quality exosomes;